Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNY0U5)

• Drug Name: BPI-9016 M Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMNY0U5

Molecule-Related Drug Atlas

Drug(s) Targeting Proto-oncogene c-Met (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[3]
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[4]
Amivantamab	DMZ7AMY	Non-small-cell lung cancer	2C25	Approved	[5]
Capmatinib	DMYCXKL	Non-small-cell lung cancer	2C25.Y	Approved	[6]
Tepotinib	DMUQ0E8	Non-small-cell lung cancer	2C25	Approved	[7]
RG3638	DMTQJE0	Gastric adenocarcinoma	2B72	Phase 3	[8]
Savolitinib	DMALFKX	Renal cell carcinoma	2C90	Phase 3	[9]
Beperminogene perplasmid	DM6RWBN	Critical limb ischemia	BD4Y	Phase 3	[10]
Tivantinib	DMNVP8Q	Hepatocellular carcinoma	2C12.02	Phase 3	[11]
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[8]

Drug(s) Targeting Tyrosine-protein kinase UFO (AXL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gilteritinib	DMTI0ZO	Acute myeloid leukaemia	2A60	Approved	[9]
MGCD265	DMRPCF2	Non-small-cell lung cancer	2C25.Y	Phase 2	[12]
BI-505	DMSZQHX	Multiple myeloma	2A83	Phase 2	[13]
Bemcentinib	DM0YCPL	Myelodysplastic syndrome	2A37	Phase 2	[14]
BGB-324	DMDI43Y	Breast cancer	2C60-2C65	Phase 2	[15]
Mecbotamab vedotin	DMU5KH4	Ovarian cancer	2C73	Phase 2	[16]
ONO-7475	DMV6GX7	Acute leukaemia	2A60	Phase 1/2	[9]
ONO-7475	DMV6GX7	Acute leukaemia	2A60	Phase 1/2	[17]
TP-0903	DMHTG8P	Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[9]
Enapotamab vedotin	DM1PQJO	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proto-oncogene c-Met (MET)	TTNDSF4	MET_HUMAN	Inhibitor	[2]
Tyrosine-protein kinase UFO (AXL)	TTZPY6J	UFO_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT02478866) Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [2] First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. J Hematol Oncol. 2020 Jan 16;13(1):6.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Clinical pipeline report, company report or official report of Exelixis (2011).
• [5] Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
• [12] Company report (Mirati Therapeutics: formerly MethylGene)
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. J Thorac Oncol. 2020 Jun;15(6):973-999.
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1835).
• [16] Clinical pipeline report, company report or official report of BioAtla
• [17] Clinical pipeline report, company report or official report of Ono Pharmaceutical.
• [18] Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight. 2019 Nov 1;4(21):e128199.